Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
Table 4
Baseline clinical laboratory tumor characteristics of the inside Milan criteria patients: significant differences only.
Characteristic
All inside MC eligibility
Lost MC eligibility
Maintained MC eligibility
value
Total number of patients
n = 59
n = 10
n = 49
ECOG performance status
0
41 (69%)
4 (40%)
37 (76%)
0.04
1
14 (24%)
5 (50%)
9 (18%)
2
2 (3%)
1 (10%)
1 (2%)
3
2 (3%)
0 (0%)
2 (4%)
ALBI grade
1
22 (37%)
1 (10%)
21 (43%)
0.049
2
34 (58%)
9 (90%)
25 (51%)
3
3 (5%)
0 (0%)
3 (6%)
BCLC stage grade
0
5 (8%)
1 (10%)
4 (8%)
0.04
A
36 (61%)
3 (30%)
33 (67%)
B
0 (0%)
0 (0%)
0 (0%)
C
16 (27%)
6 (60%)
10 (21%)
D
2 (3%)
0 (0%)
2 (4%)
Baseline symptoms
Fatigue
9 (15%)
4 (40%)
5 (10%)
0.03
Abdominal pain
9 (15%)
5 (50%)
4 (8%)
0.005
Baseline laboratory levels
Albumin (g/dL)
3.7 ± 0.5
3.3 ± 0.4
3.8 ± 0.5
0.003
The symbol indicates a significant value. MC = Milan criteria; ECOG = Eastern Cooperative Oncology Group; ALBI = albumin-bilirubin; BCLC = Barcelona Clinic Liver Cancer.
